Last reviewed · How we verify

NCT04046406

Pelvic Pain Treated With MR-guided Cryoanalgesia

Withdrawn NA Last updated 18 April 2023
What this trial tests

NA trial testing MR neurography-guided cryoanalgesia in Pelvic Pain Syndrome. Withdrawn.

Timeline
13 November 2019
Primary endpoint
1 January 2023
1 January 2023

Quick facts

Lead sponsorJohns Hopkins University
PhaseNA
StatusWithdrawn
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Start date13 November 2019
Primary completion1 January 2023
Estimated completion1 January 2023
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Johns Hopkins University

Who can join

Adults 18 to 100, any sex, with Pelvic Pain Syndrome or Groin Pain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Pelvic pain syndromes have a high prevalence of up to 8% in the general population and up to 50% following pelvic trauma and pelvic surgery. While medical management is the initial therapeutic step, it is often ineffective with surgical decompression and resection of the putative nerves being the ultima ratio. Cryoablation can induce long-lasting nerve conduction blocks with resultant pain relief for several months. The objective of this study is to evaluate the effectiveness of magnetic resonance (MR) neurography-guided cryoanalgesia for the treatment of pelvic and associated pain syndromes.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Pelvic Pain Syndrome

Currently open trials in the same condition.

Other Johns Hopkins University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04046406.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing